formulation-for-subcutaneous-delivery-of-bispecifics
The shift to subcutaneous bispecifics offers immense patient convenience and market growth, but developing stable, high-concentration formulations presents significant hurdles. Discover the critical challenges in SC formulation for bispecifics and how to overcome them.
Menu
A Market Moving Towards Easier Patient Delivery
The Big Challenges and How We're Tackling Them
How Leukocare Can Help with These Challenges [20, 21]
What We Bring to Our Partners
FAQ
1. The High-Concentration Viscosity Problem [8, 9]:
2. The Stability and Aggregation Puzzle [13]:
3. The Manufacturing and Scalability Hurdles:
The Next Big Thing in Biologics: Cracking the Subcutaneous Bispecific Puzzle
Bispecific antibodies aren't just a hopeful idea anymore; they're a real game-changer in treatment, especially for cancer [1]. The market is seeing explosive growth, with projections reaching over $220 billion by 2032 [2]. For those of us in CMC and drug product development, this progress means one thing for us: moving these complex molecules from intravenous (IV) to subcutaneous (SC) delivery. This shift is what patients and clinicians are asking for: a move toward convenience, less time in the clinic, and greater autonomy over their treatment.
Getting a high-dose bispecific into a stable, low-volume SC formulation is one of the toughest challenges we face [3]. It requires a different way of thinking about formulation development, moving beyond traditional, linear approaches to embrace a more predictive and adaptable strategy.
A Market Moving Towards Easier Patient Delivery
It's clear what's happening. While IV administration currently dominates the bispecifics market, the subcutaneous segment is projected to be the fastest-growing. The reasons are simple [4]: SC injections can often be self-administered at home, making things easier for patients and healthcare systems. This patient-centric driver is pushing companies to innovate, with successful SC delivery becoming a big advantage in the market.
This isn't just about patient preference; it’s about whether the product will even work [7]. For many indications, especially in chronic disease or maintenance therapy settings, getting frequent IV infusions isn't a long-term fix. The future of many bispecific programs depends on our ability to successfully figure out SC delivery.
The Big Challenges and How We're Tackling Them
The path to a viable SC formulation for bispecifics has some big hurdles. These molecules are just more complicated than standard monoclonal antibodies (mAbs), often less stable and harder to make.
1. The High-Concentration Viscosity Problem [8, 9]:
To deliver a high dose in a small volume (typically 1-2 mL) suitable for SC injection, we need highly concentrated protein formulations, sometimes over 100 mg/mL. When concentrations get that high, proteins can stick together, making the solution really thick [10]. A solution that is too thick is hard to get out of the vial, tricky to inject, and can hurt the patient. The generally accepted limit for injectability is around 20-25 mPa·s.
How it's being solved: The primary strategy involves the careful selection of viscosity-reducing excipients. Amino acids like arginine, proline, and glycine are often used to stop proteins from sticking together [10]. Research shows that combining certain excipients can have a combined, super-effective effect, allowing for viscosity reduction at lower total excipient concentrations, which is better for overall stability [12]. Optimizing the formulation's pH is also super important because it changes the protein's charge, which really affects how thick it gets [13].
2. The Stability and Aggregation Puzzle [13]:
Bispecific antibodies, with their often-asymmetrical structures and engineered domains, can be way less stable than traditional mAbs. They tend to clump up, which can make them less effective and, more importantly, might cause an immune reaction [14, 16]. This instability is always a worry during development, from manufacturing to long-term storage [15].
How it's being solved: It's all about finding the right conditions early. This involves screening various buffer systems and stabilizers to identify what keeps the molecule happy. Histidine and citrate buffers are common, and sugars like sucrose and trehalose are often added to protect them when frozen and keep their shape [14, 16]. Surfactants such as polysorbate 80 are also used to stop clumping at surfaces [12, 17]. The goal is to build a strong formulation that can handle being made, shipped, and stored [12].
3. The Manufacturing and Scalability Hurdles:
A formulation that works in the lab must also be made in large amounts. High-viscosity solutions can be a big issue during processing, especially during the ultrafiltration/diafiltration (UF/DF) step. Pumping thick liquids needs a lot of pressure, which could damage equipment or even the molecule itself.
How it's being solved: Making the process better is just as important as the formulation. Techniques like single-pass tangential flow filtration (TFF) can handle thick solutions better. Additionally, designing the formulation with manufacturability in mind from the start, for example, by selecting excipients that are effective at reducing viscosity even at processing temperatures, can avoid big problems down the line [18, 19]. The FDA's guidance for bispecifics says that even though many development steps are like mAbs, their unique formats mean we need to pay extra attention to quality, stability, and how they're made.
How Leukocare Can Help with These Challenges [20, 21]
At Leukocare, we tackle these challenges head-on, always starting with data. We recognize that we often don't have much material, and deadlines are tight. That's why we've stopped doing slow, trial-and-error tests.
We use predictive modeling and advanced analytics to figure out the best formulation options for a specific molecule. By combining AI predictions with quick, small-scale tests, we can find good formulation options much faster and with less material [22]. This allows us to focus our efforts on a smaller, more specific set of experiments (DoE), really digging into the best conditions [23].
This isn't just about finding a solution; it's about finding the right solution. We look at how excipients, pH, and processing all work together to develop a formulation that is stable, easy to inject, and also easy to make and strong. Our work is designed to give you a clear path forward, backed by data, even for the trickiest bispecifics to formulate.
What We Bring to Our Partners
For a CMC leader, running a bispecific program means always balancing speed, risk, and what you have. Our goal is to tip that balance in your favor.
Making Your Program Less Risky: By using predictive tools, we spot potential problems like aggregation or high viscosity early, allowing for fixing them before they happen instead of just reacting. This gives you the data and confidence to make big development decisions.
Speeding Things Up: Our data-driven process really cuts down the time spent looking for the right formulation. We help you get to a stable, working formulation quicker, speeding up the path to IND and, ultimately, to patients.
Being a Real Partner: We see ourselves as part of your team. We bring a strategic view, working closely to solve tough challenges. Whether it's dealing with a new type of drug or figuring out how to stabilize a really tricky molecule, our focus is on providing structure, speed, and real results, all backed by solid data.
FAQ
How do you handle the high viscosity of concentrated bispecifics?
We do two main things. First, we use predictive models to screen for molecular characteristics that might lead to high viscosity. Second, we design and execute targeted experiments screening a library of excipients, including amino acids and sugars, known to reduce viscosity. We really look at how different excipients work together to find the best solution that keeps things stable.
Our molecule is particularly unstable [24]. How does your process address this early on?
We address stability from day one. Our initial screening process uses quick methods to check how stable a molecule is across many pH levels and with different stabilizers. This allows us to quickly find a "safe zone" for the molecule. We then build the formulation around this, focusing on conditions that protect against things like clumping or chemical changes.
We already have an established relationship with another provider. How is working with you different?
We get that managing partnerships can be tricky. Many of our clients hire us to solve a specific, complex problem that their current partners might not be set up for, such as issues like poor freeze-drying stability, thick solutions with new drugs, or particles forming. We often begin with a small pilot project to show how our data-driven approach works and prove our worth. Our goal is to support and lighten the load for your internal teams, not replace or take over what's already there.
What does a typical project look like?
A project typically starts with a deep dive into the molecule and what we need to achieve. From there, we use our predictive tools to design a first, wide-ranging screen using just a little bit of material. Based on that data, we work with you to plan more specific experiments (DoE) to fine-tune the formulation. Throughout the process, we provide clear updates and recommendations based on data, so you always know what's happening and why we chose the final formulation.
